Clinical trial / 2008
High-dose intravenous ascorbic acid was safe but did not display objective anticancer activity.
In a phase I dose-finding study, patients with advanced cancer received infusions of ascorbic acid ranging from 0.4 to 1.5 g/kg three times weekly. Toxicity and adverse events were minimal across all dose groups. However, no participant showed an objective anticancer response.
- Study type
- Phase I non-randomized clinical trial
- Who was studied
- Patients with advanced cancer or hematologic malignancy
- What was measured
- Adverse events, toxicity, and objective anticancer response
THE PAPER
Phase I clinical trial of i.v. ascorbic acid in advanced malignancy.
Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K, Rousseau C, Robitaille L, Miller WH. Ann Oncol, 2008.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.